On follow-up of patients with NSCLC BM in our study, we surprisingly found the changes in serum levels of CTSF preceded the changes in imaging findings by an average of approximately 1–3 months in 7 patients, which strongly suggest the benefit of frequent measurements of CTSF during therapy to detect disease progression. Here, CTSF is linked to non-small cell lung carcinoma.